Arecor Therapeutics plc (AREC.L) LSE
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Arecor Therapeutics plc
Address
Chesterford Research Park
Little Chesterford, EX CB10 1XL
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1223 426 060
Website
Sector
Healthcare
Industry
Biotechnology
Employees
33
First IPO Date
June 03, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Sarah Jennifer Howell | Chief Executive Officer & Executive Director | 520,000 | 1975 |
| David J. Ellam | Chief Financial Officer & Executive Director | 321,389 | 1964 |
| Jan Jezek | Chief Scientific Officer | 0 | N/A |
| David Gerring | Chief Development Officer | 0 | N/A |
Description
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
